The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial [27] and the Study of Heart and Kidney Protection with Empagliflozin (EMPA-KIDNEY) trial [28] provided strong evidence that SGLT2 inhibitors can reduce proteinuria and the risk of progression to end-stage renal disease and renal and cardiovascular death in patients with diabetic and non-diabetic CKD. Here, SLC5A2 is linked to chronic kidney disease.